Physician profile
Suzanne Tormoen
NPI 1356309496
$2,522.19
in general payments reported to CMS, 2019-2025
26 companies · $53.65 in 2025
The $53.65 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $641 · 2020: $458 · 2021: $694 · 2022: $320 · 2023: $211 · 2024: $145 · 2025: $53.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $409.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $457.70 | 2019-2024 | Breztri |
| Novo Nordisk INC | $445.24 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $300.26 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $248.83 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $169.05 | 2022-2025 | |
| Cardiovascular Systems INC. | $161.87 | 2021 | |
| Lilly USA, LLC | $116.87 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $97.10 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.02 | 2019 | |
| Amgen INC. | $52.35 | 2019-2021 | |
| Exact Sciences Corporation | $51.61 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $48.81 | 2019-2021 | |
| Abbott Laboratories | $43.53 | 2021-2022 | |
| Abbvie INC. | $40.81 | 2021 | |
| Celgene Corporation | $30.38 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $29.99 | 2019 | |
| Mylan Specialty L.P. | $29.10 | 2019-2020 | |
| Amarin Pharma, INC. | $20.83 | 2020 | |
| Endo Pharmaceuticals INC. | $18.53 | 2019 | |
| Shire North American Group INC | $16.20 | 2019 | |
| Eisai INC. | $15.62 | 2021 | |
| Glaxosmithkline, LLC. | $15.05 | 2023 | Trelegy Ellipta |
| Currax Pharmaceuticals LLC | $13.79 | 2021 | |
| Boston Scientific Corporation | $13.64 | 2025 | Ams 700 |
| Novartis Pharmaceuticals Corporation | $13.57 | 2021 | |
| Astellas Pharma US INC | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Tormoen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.